Implementation of the Medicinal Cannabis Scheme in New Zealand
Authors: Rychert M et al.
Summary: While New Zealand’s Medicinal Cannabis Scheme (MCS) has successfully established a domestic production sector, reduced prices and provided alternatives to illegal supply, there may also be unintended negative consequences. These were the findings of an analysis of the MCS since implementation in 2020. The analysis found that the quarterly supply of medicinal cannabis products has increased fourteenfold since implementation, with most products now THC-dominant rather than CBD and in the form of dried cannabis flower rather than oral liquids/oils. Prices of products have declined to be comparable with the illegal market. While specialised private cannabis clinics have expanded patient access, inequities persist due to expense, disproportionately affecting Māori and those on lower incomes.
Reference: N Z Med J. 2024;137(1604):73-86.
Abstract
Post-pandemic increase in invasive group A strep infections in New Zealand
Authors: Ammar S et al.
Summary: A study of invasive group A streptococcal (iGAS) infections in New Zealand between 2017 and 2023 has reported findings consistent with those of many other high-income countries. National surveillance data revealed a sharp increase in iGAS in 2023, notably among children aged under ten years. Māori and Pacific peoples were disproportionately affected. In 2022-2023, the emm1 and emm12 strains were commonly reported, and there was a moderate correlation between iGAS and acute respiratory infection. After adjustment for ethnicity, sex and age, there was a significant decrease in iGAS during COVID-19 restrictions, which increased after restrictions were relaxed. The study authors noted that iGAS will become a notifiable disease in New Zealand in late 2024, which should help with monitoring and public health responses.
Reference: Infect Public Health. 2024;17(11):102545.
Abstract